In contrast, it would also be detrimental in tumor conditions, i.e., by providing suppression capacity to tumor-specific CD39+ CD8+ T cells that are chronically stimulated by tumor antigenic persistence. This evidence concerns the gene ENTPD1 and neoplasm.